Skip to main content Accessibility help
×
Home
Hostname: page-component-768ffcd9cc-w9xp6 Total loading time: 0.611 Render date: 2022-12-06T21:19:40.166Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions

Published online by Cambridge University Press:  27 January 2015

John Howl*
Affiliation:
Molecular Pharmacology Group, Research Institute in Healthcare Science, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, UK
Sarah Jones
Affiliation:
Molecular Pharmacology Group, Research Institute in Healthcare Science, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, UK
*
*Corresponding author: John Howl, Molecular Pharmacology Group, Research Institute in Healthcare Science, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, UK. E-mail: J.Howl@wlv.ac.uk

Abstract

Cell-penetrating peptides (CPPs) are reliable vehicles for the target-selective intracellular delivery of therapeutic agents. The identification and application of numerous intrinsically bioactive CPPs, now designated as bioportides, is further endorsement of the tremendous clinical potential of CPP technologies. The refinement of proteomimetic bioportides, particularly sequences that mimic cationic α-helical domains involved in protein-protein interactions (PPIs), provides tremendous opportunities to modulate this emergent drug modality in a clinical setting. Thus, a number of CPP-based constructs are currently undergoing clinical trials as human therapeutics, with a particular focus upon anti-cancer agents. A well-characterised array of synthetic modifications, compatible with modern solid-phase synthesis, can be utilised to improve the biophysical and pharmacological properties of bioportides and so achieve cell-and tissue-selective targeting in vivo. Moreover, considering the recent successful development of stapled α-helical peptides as anti-cancer agents, we hypothesise that similar structural modifications are applicable to the design of bioportides that more effectively modulate the many interactomes known to underlie human diseases. Thus, we propose that stapled-helical bioportides could satisfy all of the clinical requirements for metabolically stable, intrinsically cell-permeable agents capable of regulating discrete PPIs by a dominant negative mode of action with minimal toxicity.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Derossi, D. et al. (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. Journal of Biological Chemistry 269, 10444-10450 Google ScholarPubMed
2 Vivès, E., Brodin, P. and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. Journal of Biological Chemistry 272, 16010-16017 CrossRefGoogle ScholarPubMed
3 Futaki, S. et al. (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. Journal of Biological Chemistry 276, 5836-5840 CrossRefGoogle ScholarPubMed
4 Jones, S. et al. (2010) Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. Chemistry & Biology 17, 735-744 CrossRefGoogle ScholarPubMed
5 Cronican, J. et al. (2011) A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chemistry & Biology 18, 833-838 CrossRefGoogle ScholarPubMed
6 Langel, Ü. (ed.) (2007) Handbook of Cell-Penetrating Peptides, CRC Press, Boca Raton, FL, USA Google Scholar
7 Mae, M. and Langel, Ü. (2006) Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Current Opinion in Pharmacology 6, 509-514 CrossRefGoogle ScholarPubMed
8 Svensen, N., Walton, J.G.A. and Bradley, M. (2012) Peptides for cell-selective drug delivery. Trends in Pharmacological Sciences 33, 186-192 CrossRefGoogle ScholarPubMed
9 Duchard, F. et al. (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 849-866 Google Scholar
10 Richard, J.P. et al. (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. Journal of Biological Chemistry 278, 585-590 CrossRefGoogle ScholarPubMed
11 Rothbard, J.B., Jessop, T.C. and Wender, P.A. (2005) Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Advanced Drug Delivery Reviews 57, 495-504 CrossRefGoogle ScholarPubMed
12 Meade, B.R. and Dowdy, S.F. (2007) Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Advanced Drug Delivery Reviews 60, 530-536 CrossRefGoogle ScholarPubMed
13 Räägel, H. et al. (2013) Cell-penetrating peptide secures an efficient endosomal escape of an intact cargo upon a brief photo-induction. Cellular and Molecular Life Sciences 70, 4825-4839 CrossRefGoogle ScholarPubMed
14 Verdurmen, W.P.R. and Brock, R. (2010) Biological responses towards cationic peptides and drug carriers. Trends in Pharmacological Science 32, 116-124 CrossRefGoogle ScholarPubMed
15 Howl, J. and Jones, S. (2008) Proteomimetic cell penetrating peptides. International Journal of Peptide Research and Therapeutics 14, 359-366 CrossRefGoogle Scholar
16 Howl, J. et al. (2012) Bioportide: an emergent concept of bioactive cell penetrating peptide. Cellular and Molecular Life Sciences 69, 2951-2966 CrossRefGoogle Scholar
17 Lukanowska, M., Howl, J. and Jones, S. (2013) Bioportides: bioactive cell penetrating peptides that modulate cellular dynamics. Biotechnology Journal 8, 918-930 CrossRefGoogle ScholarPubMed
18 Kiosses, W.B. et al. (2002) A dominant negative p65 PAK peptide inhibits angiogenesis. Circulation Research 90, 697-702 CrossRefGoogle ScholarPubMed
19 Gangoso, E. et al. (2014) A cell-penetrating peptide based on the interaction between C-src and connexin43 reverses glioma cell phenotype. Cell Death and Disease, 5, e1053 CrossRefGoogle Scholar
20 Khavinson, V.Kh. et al. (2013) Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Biology Bulletins Reviews 3, 451-455 CrossRefGoogle Scholar
21 Jones, S. and Thornton, J.M. (1995) Protein-protein interactions: a review of protein dimer structures. Progress in Biophysics and Molecular Biology 63, 31-65 CrossRefGoogle ScholarPubMed
22 Smith, M.C. and Gestwicki, J.E. (2012) Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Reviews in Molecular Medicine 14, e16 CrossRefGoogle ScholarPubMed
23 Ivanov, A.A., Khuri, F.R. and Fu, H. (2013) Targeting protein-protein interactions as an anticancer strategy. Trends in Pharmacological Sciences 34, 393-400 CrossRefGoogle ScholarPubMed
24 Arkin, M.R. and Wells, J.A. (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Reviews in Drug Discovery 3, 301-317 CrossRefGoogle ScholarPubMed
25 Hopkins, A.L. and Groom, C.R. (2002) The druggable genome. Nature Reviews Drug Discovery 1, 727-730 CrossRefGoogle ScholarPubMed
26 Thiel, P., Kaiser, M. and Ottmann, C. (2012) Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Angewandte Chemie International Edition 51, 2012-2018 CrossRefGoogle ScholarPubMed
27 Rask-Andersen, M., Almén, M.S. and Schiöth, H.B. (2011) Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery 10, 579-590 CrossRefGoogle ScholarPubMed
28 Hansen, M., Kilk, K. and Langel, Ü. (2008) Predicting cell-penetrating peptides. Advanced Drug Delivery Reviews 60, 572-579 CrossRefGoogle ScholarPubMed
29 Hällbrink, M. et al. (2005) Prediction of cell-penetrating peptides. International Journal of Peptide Research and Therapeutics 11, 249-259 CrossRefGoogle Scholar
30 Jochim, A.L. and Arora, P.S. (2009) Assessment of helical interfaces in protein-protein interactions. Molecular BioSystems 5, 924-926 CrossRefGoogle ScholarPubMed
31 Verdine, G.L. and Hillinski, G.J. (2012) Stapled peptides for intracellular drug targets. Methods in Enzymology 503, 3-33 CrossRefGoogle ScholarPubMed
32 Mullard, A. (2012) Protein-protein interaction inhibitors get into the groove. Nature Reviews Drug Discovery 11, 173-175 CrossRefGoogle Scholar
33 Zhao, Y., Bernard, D. and Wang, S. (2013) Small molecule inhibitors of MDM2-p53 and MDMX-p53 interactions as new cancer therapeutics. BioDisovery 8, 1-15 Google Scholar
34 White, A.W., Westwell, A.D. and Brahemi, G. (2008) Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine 10, e8 CrossRefGoogle Scholar
35 Pooga, M. et al. (1998) Cell penetration by transportan. FASEB Journal 12, 67-77 Google ScholarPubMed
36 Soomets, U. et al. (2000) Deletion analogues of transportan. Biochimica et Biophysica Acta 1467, 165-176 CrossRefGoogle ScholarPubMed
37 Jones, S. et al. (2008) Mitoparan and target-selective chimeric analogues: membrane translocation and intracellular redistribution induces mitochondrial apoptosis. Biochmica et. Biophyica Acta 1783, 849-863 CrossRefGoogle ScholarPubMed
38 Vasconcelos, L., Pärn, K. and Langel, Ü. (2013) Therapeutic potential of cell-penetrating peptides. Therapeutic Delivery 4, 573-591 CrossRefGoogle Scholar
39 Vivès, E., Schmidt, J. and Pèlegrin, A. (2008) Cell-penetrating and cell-targeting peptides in drug delivery. Biochimica et Biophysica Acta 1786, 126-138 Google Scholar
40 Johnson, R.M., Harrison, S.D. and Maclean, D. (2011) Therapeutic applications of cell-penetrating peptides. Methods in Molecular Biology 683, 535-551 CrossRefGoogle ScholarPubMed
41 Tréhin, R. and Merkle, H.P. (2004) Chances and pitfalls of cell penetrating peptides for cellular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 58, 209-223 CrossRefGoogle ScholarPubMed
42 Gump, J.M. and Dowdy, S.F. (2007) Tat transduction: the molecular mechanism and therapeutic prospects. Trends in Molecular Medicine 13, 443-448 CrossRefGoogle ScholarPubMed
43 Aina, O.H. et al. (2007) From combinatorial chemistry to cancer-targeting peptides. Molecular Pharmacology 4, 631-651 CrossRefGoogle ScholarPubMed
44 Rivinoja, A. and Laakkonen, P. (2011) Identification of homing peptides using the in vivo phage display technology. Methods in Molecular Biology 683, 401-415 CrossRefGoogle ScholarPubMed
45 Nguyen, Q.T. et al. (2010) Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proceedings of the National Academy of Sciences USA 107, 4317-4322 CrossRefGoogle ScholarPubMed
46 Weinstain, R. et al. (2013) In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides. Journal of the American Chemical Society 136, 874-877 CrossRefGoogle ScholarPubMed
47 Jin, E. et al. (2013) Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery. Journal of the American Chemical Society 135, 933-940 CrossRefGoogle ScholarPubMed
48 Sidhu, S.S. et al. (2000) Phage display for selection of novel binding peptides. Methods in Enzymology, 328, 333-363 CrossRefGoogle ScholarPubMed
49 Eriste, E. et al. (2013) Peptide-based glioma-targeted drug delivery vector gHope2. Bioconjugate Chemistry 24, 305-313 CrossRefGoogle ScholarPubMed
50 Pollaro, L. and Heinis, C. (2010) Strategies to prolong the plasma residence time of peptide drugs. Medicinal Chemistry Communications 1, 319-324 CrossRefGoogle Scholar
51 Turk, B. (2006) Targeting proteases: successes, failures and future prospects. Nature Reviews Drug Discovery 5, 785-799 CrossRefGoogle ScholarPubMed
52 Järver, P., Mäger, I. and Langel, Ü. (2010) In vivo biodistribution and efficacy of peptide mediated delivery. Trends in Pharmacological Sciences 31, 528-535 CrossRefGoogle ScholarPubMed
53 Guichard, G. et al. (1994) Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proceedings of the National Academy of Sciences USA 91, 9765-9769 CrossRefGoogle ScholarPubMed
54 Werle, M. and Bernkop-Schnürch, A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367 CrossRefGoogle ScholarPubMed
55 Wender, P.A. et al. (2008) The design of guanidinium-rich transporters and their internalization mechanisms. Advanced Drug Delivery Reviews 60, 452-472 CrossRefGoogle ScholarPubMed
56 Simon, R.J. et al. (1992) Peptoids: a modular approach to drug discovery. Proceedings of the National Academy of Sciences USA 89, 9367-9371 CrossRefGoogle ScholarPubMed
57 McGregor, D.P. (2008) Discovering and improving novel peptide therapeutics. Current Opinion in Pharmacology 8, 616-619 CrossRefGoogle Scholar
58 Holm, T. et al. (2011) Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochimica et Biophysica Acta 1808, 1544-1551 CrossRefGoogle ScholarPubMed
59 Craik, D.J. et al. (2013) The future of peptide-based drugs. Chemical Biology and Drug Design, 81, 136-147 CrossRefGoogle ScholarPubMed
60 Olmez, E.F. and Akbulut, B.S. (2012) Protein-peptide interactions revolutionize drug development. In Binding Protein (Abdelmohsen, K. ed.), ISBN: 978-953-51-0758-3, InTech, DOI: 10.5772/48418 Google Scholar
61 Schwyzer, R. (1977) ACTH: a short introductory review. Annals of the New York Academy of Sciences 297, 3-26 CrossRefGoogle ScholarPubMed
62 Johansson, H.J. et al. (2008) Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Molecular Therapy 16, 115-123 CrossRefGoogle ScholarPubMed
63 Löfgren, K. et al. (2008) Antiprion properties of prion protein-derived cell-penetrating peptides. FASEB Journal 22, 2177-2184 CrossRefGoogle ScholarPubMed
64 McGuire, M.J. et al. (2014) Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. Science. Report. 4, 4480; doi:10.1038/srep04480 CrossRefGoogle ScholarPubMed
65 Li, K. et al. (2014) Targeting acute myeloid leukemia with a proapototic peptide conjugated to a toll-like receptor 2-mediated cell-penetrating peptide. International Journal of Cancer 134, 692-702 CrossRefGoogle Scholar
66 Crowley, P.B. and Golovin, A. (2005) Cation-π interactions in protein-protein interfaces. PROTEINS: Structure, Function and Bioinformatics 59, 231-239 CrossRefGoogle ScholarPubMed
67 Moreira, I.S., Fernandes, P.A. and Ramos, M.J. (2007) Hot spots-A review of the protein-protein interface determinant amino acid residues. Proteins 68, 803-812 CrossRefGoogle ScholarPubMed
68 Östlund, P. et al. (2005) Cell-penetrating mimics of agonist-activated G-protein coupled receptors. International Journal of Peptide Research and Therapeutics 11, 237-247 CrossRefGoogle Scholar
69 Lewis, P.A. and Manzoni, C. (2012) LRRK2 and human disease: a complicated question or a question of complexes? Science Signaling 5, pe2 CrossRefGoogle ScholarPubMed
70 Holm, P. et al. (2006) Studying the uptake of cell-penetrating peptides. Nature Protocols 1, 1001-1005 CrossRefGoogle ScholarPubMed
71 Burlina, F. et al. (2005) Quantification of the cellular uptake of cell-penetrating peptides by MALDI-TOF mass spectrometry. Angewandte Chemie International Edition 44, 4244-4247 CrossRefGoogle ScholarPubMed
72 Jones, S. and Howl, J. (2012) Enantiomer-specific bioactivities of peptidomimetic analogues of mastoparan and mitoparan: characterization of inverso mastoparan as a highly efficient cell penetrating peptide. Bioconjugate Chemistry 23, 47-56 CrossRefGoogle ScholarPubMed
73 Hällbrink, M. et al. (2004) Uptake of cell-penetrating peptides is dependent on peptide-to-cell ratio rather than on peptide concentration. Biochimica et Biophysica Acta 1667, 222-228 CrossRefGoogle ScholarPubMed
74 Gomez, J.A. et al. (2010) Cell-penetrating penta-peptides (CPP5 s): measurement of cell entry and protein-transduction activity. Pharmaceuticals 3, 3594-3613 CrossRefGoogle Scholar
75 Sagan, S. et al. (2010) Quantification and proteolytic analysis of cell-penetrating peptides and cargo in eukaryote cells. In Membrane Active Peptides: Methods and Results on Structure and Function (Castanho, M.A.R.B., ed.), pp. 247-270, International University Line Publishers, La Jolla, CA, USA Google Scholar
76 Dosil, M. et al. (1998) Dominant-negative mutations in the G-protein-coupled α-factor receptor map to the extracellular ends of the transmembrane segments. Molecular and Cellular Biology 18, 5981-5991 CrossRefGoogle ScholarPubMed
77 Williams, D.A. et al. (2000) Dominant negative mutation of the hematopoetic-specific Rho-GTPase, Rac2, is associated with human phagocyte immunodeficiency. Blood 96, 1646-1654 Google ScholarPubMed
78 Harada, Y. et al. (2010) Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenecity in bladder cancer cells. Cancer Research 70, 5829-5839 CrossRefGoogle Scholar
79 McCusker, C.T. et al. (2007) Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. Journal of Immunology 179, 2556-2564 CrossRefGoogle ScholarPubMed
80 Johansson, H.J., El Andaloussi, S. and Langel, Ü. (2011) Mimicry of protein function with cell-penetrating peptides. Methods in Molecular Biology 683, 233-247 CrossRefGoogle ScholarPubMed
81 Farias, E.F. et al. (2010) Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proceedings of the National Academy of Sciences USA 107, 11811-11816 CrossRefGoogle ScholarPubMed
82 Smith, L.J. et al. (1996) The concept of a random coil. Residual structure sin peptides and denatures proteins. Current Biology Folding & Design 1, R95-R106 Google ScholarPubMed
83 Deshayes, S. et al. (2007) Interactions of cell-penetrating peptides with model membranes. In Handbook of Cell-Penetrating Peptides (Langel, Ü., ed.), pp. 139-160, CRC Press, Boca Raton, FL, USA Google Scholar
84 Schwyzer, R. (1992) Conformations and orientations of amphiphilic peptides induced by artificial lipid membranes: correlations with biological activity. Chemtracts: Biochemistry and Molecular Biology 3, 347-379 Google Scholar
85 Ladokhin, A.S. and White, S.H. (1999) Folding of amphipathic α-helices on membranes: energetics of helix formation by melittin. Journal of Molecular Biology 285, 1363-1369 CrossRefGoogle ScholarPubMed
86 Jones, S. and Howl, J. (2009) Mastoparans. In Bioactive Peptides (Howl, J. and Jones, S., eds), pp. 429-445, CRC Press, Boca Raton, FL, USA CrossRefGoogle Scholar
87 Bechara, C. et al. (2013) Trytophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. FASEB Journal, 27, 738-749 CrossRefGoogle Scholar
88 Esbjörner, E.K., Gräslund, A. and Nordén, B. (2007) Membrane interactions of cell-penetrating peptides. In Handbook of Cell-Penetrating Peptides (Langel, Ü., ed.), pp. 109-137, CRC Press, Boca Raton, FL, USA Google Scholar
89 Grubbs, R.H. (2004) Olefin metathesis. Tetrahedron 60, 7117-7140 CrossRefGoogle Scholar
90 Kim, Y.-W., Kutchuklan, P.S. and Verdine, G.L. (2010) Introduction of all-hydrocarbon i,i+3 staples into α-helices via ring-closing olefin metathesis. Organic Letters 12, 3046-3049 CrossRefGoogle ScholarPubMed
91 Kim, Y.-W. and Verdine, G.L. (2009) Stereochemical effects of all-hydrocarbon tethers in i.i+4 stapled peptides. Bioorganic and Medicinal Chemistry Letters 19, 2533-2536 CrossRefGoogle ScholarPubMed
92 Kim, Y-W., Grossmann, T.N. and Verdine, G.L. (2011) Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nature Protocols 6, 761-771 CrossRefGoogle ScholarPubMed
93 Le Guezennec, X., Vriend, G. and Stunnenberg, H.G. (2004) Molecular determinants of the interaction of Mad with the PAH2 domain of mSin3. Journal of Biological Chemistry 279, 25823-25829 CrossRefGoogle ScholarPubMed
94 Ponting, C.P. and Russell, R.R. (2002) The natural history of protein domains. Annual Review of Biophysics and Biomolecular Structure 31, 45-71 CrossRefGoogle ScholarPubMed
95 Basu, M.K. et al. (2008) Evolution of protein domain promiscuity in eukaryotes. Genome Research 18, 449-461 CrossRefGoogle ScholarPubMed
96 Pawson, T. and Nash, P. (2000) Protein-protein interactions define specificity in signal transduction. Genes & Development 14, 1027-1047 Google ScholarPubMed
97 Wilson, A.J. (2009) Inhibition of protein-protein interactions using designed molecules. Chemical Society Reviews 38, 3289-3300 CrossRefGoogle ScholarPubMed
98 Verdine, G.L. and Hilinski, G.J. (2012) All-hydrocarbon stapled peptides as synthetic cell-accessible mini-proteins. Drug Discovery Today: Technologies 9, e41-e47 CrossRefGoogle Scholar
99 Bedford, M.T. and Richard, S. (2005) Arginine methylation: an emerging regulator of protein function. Molecular Cell 18, 263-272 CrossRefGoogle ScholarPubMed
100 Boisvert, F.M., Chénard, C.A. and Richard, S. (2005) Protein interfaces in signaling regulated by arginine methylation. Science Signaling 15, re2 Google Scholar
101 Jones, S. and Thornton, J.M. (1996) Principles of protein-protein interactions. Proceedings of the National Academy of Sciences USA 93, 13-20 CrossRefGoogle ScholarPubMed
102 Henchey, L.K., Jochim, A.L. and Arora, P.S. (2008) Contemporary strategies for the stabilization of peptides in the α-helical conformation. Current Opinion in Chemical Biology 12, 692-697 CrossRefGoogle ScholarPubMed
103 Walensky, L.D. et al. (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 CrossRefGoogle ScholarPubMed
104 Moellering, R.E. et al. (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 CrossRefGoogle ScholarPubMed
105 Chang, Y.S. et al. (2013) Stapled αhelical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dpenedent cancer therapy. Proceedings of the National Academy of Sciences USA 110, E3445-E3454 CrossRefGoogle Scholar
106 Cheok, C.F. et al. (2011) Translating p53 into the clinic. Nature Reviews Clinical Oncology 8, 25-37 CrossRefGoogle ScholarPubMed
107 Warso, M.A. et al. (2013) A first-in-class, first-in-human, phase 1 trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquination in patients with advanced solid tumours. British Journal of Cancer 108, 1061-1071 CrossRefGoogle Scholar
108 Lipinski, C.A. (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies 1, 337-341 CrossRefGoogle ScholarPubMed
109 Vidal, M., Cusick, M.E. and Barabási, A-L. (2011) Interactome networks and human disease. Cell 144, 986-998 CrossRefGoogle ScholarPubMed
110 Gentilucci, L., De Marco, R. and Cerisoli, L. (2013) Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Current Pharmaceutical Design 16, 3185-3203 CrossRefGoogle ScholarPubMed
13
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *